We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

113 hedge funds and large institutions have $617M invested in Keros Therapeutics in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

192,133% more call options, than puts

Call options by funds: $5.77M | Put options by funds: $3K

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

56% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 25

42% more capital invested

Capital invested by funds: $433M → $617M (+$184M)

9% more funds holding

Funds holding: 104 → 113 (+9)

2.03% less ownership

Funds ownership: 72.22% → 70.18% (-2%)

Holders
113
Holders Change
+9
Holders Change %
+8.65%
% of All Funds
1.95%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
24
Increased
39
Reduced
25
Closed
15
Calls
$5.77M
Puts
$3K
Net Calls
+$5.76M
Net Calls Change
+$3.93M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$11.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.14M
3
CIBC Asset Management
CIBC Asset Management
Ontario, Canada
+$5.07M
4
SCM
Soleus Capital Management
Connecticut
+$5.06M
5
SFM
Sphera Funds Management
Israel
+$4.81M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$17M
2
OCA
Octagon Capital Advisors
New York
-$4.21M
3
Allianz Asset Management
Allianz Asset Management
Germany
-$3.82M
4
NCM
Nantahala Capital Management
Connecticut
-$2.29M
5
Morgan Stanley
Morgan Stanley
New York
-$2.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
26
Cormorant Asset Management
Massachusetts
$3.76M – – –
PHP
27
Parkman Healthcare Partners
Connecticut
$3.76M +$1.81M +52,139 +109%
Barclays
28
Barclays
United Kingdom
$3.67M +$2.21M +63,658 +188%
Renaissance Technologies
29
Renaissance Technologies
New York
$3.66M -$1.54M -44,500 -31%
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$3.46M +$3.18M +91,840 New
ACM
31
Altium Capital Management
New York
$3.31M – – –
VOYA Investment Management
32
VOYA Investment Management
Georgia
$3.29M +$3.03M +87,410 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.8M +$962K +27,744 +59%
N
34
Nuveen
North Carolina
$2.43M +$60.8K +1,753 +3%
Morgan Stanley
35
Morgan Stanley
New York
$2.31M -$2.02M -58,277 -49%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$2.16M +$691K +19,936 +53%
Bank of America
37
Bank of America
North Carolina
$2M +$497K +14,341 +37%
DCM
38
DAFNA Capital Management
California
$1.47M – – –
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$1.35M +$1.25M +36,022 New
Swiss National Bank
40
Swiss National Bank
Switzerland
$1.29M +$38.1K +1,100 +3%
UOC
41
UBS O'Connor
Illinois
$1.25M -$832K -24,000 -42%
JG
42
Jefferies Group
New York
$1.1M +$583K +16,819 +135%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$934K +$862K +24,859 New
KCM
44
Kennedy Capital Management
Missouri
$884K -$821K -23,676 -50%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$879K +$108K +3,106 +15%
PP
46
PDT Partners
New York
$853K -$862K -24,883 -52%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$844K +$777K +22,427 New
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$828K -$1.11M -32,015 -59%
CM
49
Caption Management
Oklahoma
$753K +$693K +20,000 New
Squarepoint
50
Squarepoint
New York
$749K +$76.4K +2,204 +12%
1
2
3 4 5

KROS Hedge Fund Activity: Q3 2022 in Review

113 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2022, worth a combined $617M — up 42% from $433M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new KROS positions and 15 closed out — a net gain of 9 holders — while 39 added to existing stakes and 25 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $11.9M. The largest seller was Deep Track Capital, cutting an estimated $17M.

  • 113 institutional investors held Keros Therapeutics (KROS) as of Q3 2022, up from 104 in Q2 2022.
  • Funds reported $617M of Keros Therapeutics stock for Q3 2022, up 42% quarter-over-quarter.
  • 24 funds opened new Keros Therapeutics positions in Q3 2022 and 15 closed out, a net change of +9 holders.
  • The largest Keros Therapeutics buyer in Q3 2022 was Woodline Partners, an estimated $11.9M added.
  • The largest Keros Therapeutics seller in Q3 2022 was Deep Track Capital, an estimated $17M sold.

Based on aggregated 13F filings for Q3 2022.